Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of COVID-eVax in Healthy Adults
NCT04788459Phase 2Terminated
- Sponsor
- Takis Biotech
- Start
- Feb 2021
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of COVID-eVax in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Takis Biotech. Primary endpoints: Incidence of solicited local Adverse events at the injection site at 7 days, Incidence of solicited systemic Adverse events at 7 days and 11 more. Started Feb 2021; status: terminated.
02
Drugs
COVID-eVax
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04788459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04788459.